Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 10/20 | 0.43 |
| ▸ | STK17B | O94768 | 8/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18440270 | 0.90 | JAK2 (0.49) | HDAC3HDAC1HDAC2HDAC6STK17A | |
| SCHEMBL29556741 | 0.90 | JAK2 (0.49) | HDAC3HDAC1HDAC2HDAC6STK17A | |
| SCHEMBL18488449 | 0.85 | HDAC3 (0.45) | HDAC3HDAC1HDAC2HDAC6STK17A | |
| SCHEMBL18488672 | 0.83 | MEN1 (0.50) | HDAC3HDAC1HDAC2HDAC6STK17A | |
| SCHEMBL18488360 | 0.81 | APP (0.60) | STK17ASTK17BJAK2APPCYP2D6 | |
| SCHEMBL29555879 | 0.81 | APP (0.60) | STK17ASTK17BJAK2APPCYP2D6 | |
| SCHEMBL18488325 | 0.79 | HDAC3 (0.40) | HDAC3HDAC1HDAC2HDAC6STK17A | |
| SCHEMBL18488976 | 0.78 | CYP1A2 (0.53) | APPTAAR1CYP2C19CYP1A2ALDH1A1 | |
| SCHEMBL18493897 | 0.77 | STK17B (0.43) | HDAC3HDAC1HDAC2HDAC6STK17A | |
| SCHEMBL20421838 | 0.77 | CCND3 (0.53) | STK17ASTK17BSRCTAAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| WO-2017023899-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | HDAC3 1024/4885HDAC1 805/4885HDAC2 856/4885 |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | HDAC3 1024/4885HDAC1 805/4885HDAC2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.